1. Introduction

Diagnosis of hepatitis B virus (HBV) infection requires integration of:

• Clinical findings

• HBV serology

• HBV DNA testing

• Liver biochemistry

• Assessment of hepatic fibrosis

• Imaging

• Risk assessment

No single test answers every clinical question.

The fundamental diagnostic markers are:

HBsAg

Indicates current HBV infection.

Anti-HBc

Indicates natural exposure to HBV.

Anti-HBs

Indicates immunity.

HBeAg / anti-HBe

Provide information about viral replication and immune control.

HBV DNA

Directly measures circulating viral nucleic acid and is the principal marker of viral replication.

2. Diagnostic Objectives

When evaluating a patient, HBV testing should answer several separate questions:

1. Is the patient infected with HBV now?

2. Is the infection acute or chronic?

3. Has the patient been exposed previously?

4. Is the patient immune?

5. Is HBV actively replicating?

6. Is there active hepatitis?

7. How much liver damage has occurred?

8. Does the patient require antiviral therapy?

9. Is the patient at risk of HCC or cirrhosis?

10. Could the patient reactivate HBV during immunosuppression?

3. Major HBV Diagnostic Markers

4. First-Line Test: HBsAg

Hepatitis B surface antigen

HBsAg is the primary screening marker for current HBV infection.

HBsAg positive

Means:

It may represent:

• acute HBV infection

• chronic HBV infection

• chronic infection with active hepatitis

• chronic infection with low-level replication

Therefore:

HBsAg positivity alone cannot distinguish acute from chronic infection.

5. HBsAg Persistence and Chronic Infection

The classic definition is:

HBsAg persistence ≥6 months

→ chronic HBV infection

This can be demonstrated by:

• previous documented HBsAg positivity

• serial testing

• compatible clinical/serological findings

6. HBsAg Assays

Modern laboratories commonly use:

Immunoassays

including:

• ELISA/EIA

• chemiluminescent immunoassays

• electrochemiluminescence assays

• automated high-throughput platforms

These assays detect HBsAg in serum/plasma.

7. Quantitative HBsAg

Some assays provide:

Quantitative HBsAg (qHBsAg)

reported generally in:

IU/mL

Quantitative HBsAg can provide information about:

• viral antigen burden

• disease phase

• likelihood of spontaneous HBsAg loss

• treatment response in selected settings

However:

8. Anti-HBc

Anti-HBc indicates:

Natural exposure to HBV.

It is not produced after vaccination alone.

There are two major components:

• IgM anti-HBc

• IgG anti-HBc

9. Total Anti-HBc

Total anti-HBc generally measures:

IgM + IgG anti-HBc

A positive result indicates:

It may be positive in:

• acute infection

• chronic infection

• resolved infection

• some reactivation episodes

10. IgM Anti-HBc

IgM anti-HBc is particularly useful for identifying:

Recent/acute HBV infection.

It is usually strongly positive during acute hepatitis B.

However, it can also occur during:

• severe chronic HBV exacerbations

• HBV reactivation

Therefore:

11. Anti-HBs

Anti-HBs indicates:

Immunity against HBV.

It may appear after:

• recovery from natural infection

• successful vaccination

Key distinction

Natural infection:

Anti-HBs + anti-HBc +

Vaccination:

Anti-HBs + anti-HBc −

12. HBeAg

HBeAg is a marker associated with:

• active viral replication

• high HBV DNA

• increased infectivity

However:

HBV DNA is superior for determining the amount of circulating virus.

13. Anti-HBe

Anti-HBe usually develops after:

HBeAg seroconversion

and often correlates with reduced viral replication.

But:

Anti-HBe positivity does not prove inactive infection.

HBeAg-negative chronic hepatitis can have:

• anti-HBe positive

• high HBV DNA

• elevated ALT

14. HBV DNA

HBV DNA is detected using:

Nucleic acid amplification tests (NAAT/NAT)

Most commonly:

Real-time PCR

It provides:

• qualitative detection

• quantitative measurement

Quantitative HBV DNA is usually reported as:

IU/mL

15. Why HBV DNA Is Important

HBV DNA is used to:

• establish active viral replication

• classify disease phase

• assess treatment eligibility

• monitor antiviral response

• detect virological breakthrough

• investigate suspected resistance

• assess mother-to-child transmission risk

• evaluate immunosuppression/reactivation risk

16. HBV DNA Detection

A typical molecular workflow:

Patient serum/plasma
       ↓
Nucleic acid extraction
       ↓
HBV DNA amplification
       ↓
Target-specific detection
       ↓
Quantification
       ↓
Result in IU/mL

17. PCR-Based HBV DNA Assays

Modern assays generally use:

Real-time PCR

Advantages:

• high sensitivity

• high specificity

• broad dynamic range

• quantitative results

• useful for treatment monitoring

Results should preferably be interpreted using standardized:

WHO international units (IU/mL)

rather than relying on copies/mL.

18. IU/mL vs Copies/mL

Older HBV literature frequently reported:

copies/mL

Modern clinical practice generally uses:

IU/mL

Conversion between copies/mL and IU/mL is assay-dependent and should not be treated as one universal fixed conversion factor.

19. ALT and AST

HBV diagnosis is not complete without assessing liver injury.

ALT

is particularly useful for:

• identifying active hepatitis

• assessing treatment eligibility

• monitoring disease activity

However:

20. Liver Function Tests

Assess:

• bilirubin

• albumin

• PT/INR

• AST

• ALT

• alkaline phosphatase

Important distinction

ALT/AST primarily reflect:

hepatocellular injury

whereas:

Albumin + INR + bilirubin provide information about:

hepatic functional reserve/cholestasis.

21. Complete Blood Count

The platelet count is particularly useful.

Low platelets

may suggest:

• portal hypertension

• splenomegaly

• advanced fibrosis/cirrhosis

Therefore, CBC is part of the broader assessment.

22. Fibrosis Assessment

Diagnosis of HBV infection alone is not enough.

The clinician must determine:

How much liver damage has occurred?

Methods include:

• transient elastography

• APRI

• FIB-4

• ultrasound

• liver biopsy in selected patients

23. Transient Elastography

Transient elastography estimates:

Liver stiffness

Higher stiffness generally correlates with greater fibrosis.

It is:

• non-invasive

• repeatable

• useful for longitudinal assessment

However, liver stiffness may also increase with:

• acute inflammation

• cholestasis

• congestion

Therefore:

24. APRI

AST to Platelet Ratio Index

Uses:

• AST

• platelet count

It can provide a simple estimate of advanced fibrosis/cirrhosis risk.

It is useful particularly where advanced fibrosis assessment resources are limited.

25. FIB-4

FIB-4 incorporates:

• age

• AST

• ALT

• platelet count

It can be used as another non-invasive fibrosis assessment tool.

Neither APRI nor FIB-4 replaces clinical assessment or validated elastography where available.

26. Liver Biopsy

Liver biopsy is no longer routinely required for every HBV patient.

It may be considered when:

• non-invasive tests are discordant

• disease activity is uncertain

• other liver diseases are suspected

• histological grading/staging will alter management

Histology can assess:

• necroinflammation

• fibrosis

• cirrhosis

• steatohepatitis

• alternative pathology

27. HBV Serological Interpretation — Core Table

28. The Isolated Anti-HBc Pattern

This is:

HBsAg −

Anti-HBs −

Total anti-HBc +

Possible explanations include:

1. Window period

2. Remote resolved infection with loss of anti-HBs

3. Occult HBV infection

4. False-positive anti-HBc

5. Less commonly, other serological circumstances

Therefore:

29. How to Investigate Isolated Anti-HBc

Consider:

• IgM anti-HBc

• HBV DNA

• repeat serology

• clinical history

• vaccination history

• immunosuppression risk

Simplified interpretation

Isolated anti-HBc
       ↓
IgM anti-HBc?
   ↙          ↘
Positive     Negative
   ↓            ↓
Recent       Consider:
infection    remote infection
likely       occult HBV
              false-positive

30. Acute vs Chronic HBV

Acute HBV

Typical:

• HBsAg +

• IgM anti-HBc +

• HBV DNA +

• ALT markedly elevated

Chronic HBV

Typical:

• HBsAg ≥6 months

• total anti-HBc +

• IgM anti-HBc usually negative

• HBV DNA variable

• ALT variable

31. HBeAg-Positive vs HBeAg-Negative Disease

HBeAg-positive

Often:

• high HBV DNA

• HBeAg positive

• increased infectivity

HBeAg-negative

Could represent:

• inactive chronic infection

• HBeAg-negative chronic hepatitis

• precore/core promoter variant infection

Therefore:

HBV DNA + ALT

are essential for classification.

32. Diagnosis of HBeAg-Negative Chronic Hepatitis

Typical profile:

HBsAg +

HBeAg −

anti-HBe +

HBV DNA elevated/fluctuating

ALT elevated/fluctuating

This is particularly important because:

HBeAg negativity does not equal inactivity.

33. Quantitative HBsAg — Clinical Use

qHBsAg may assist in:

• disease-phase assessment

• predicting spontaneous HBsAg clearance

• selected treatment-response assessments

• research and specialized clinical decision-making

But:

qHBsAg is not a substitute for HBV DNA.

34. HBsAg and HBV DNA Discordance

Possible patterns include:

HBsAg positive + HBV DNA negative/very low

Possible:

• inactive infection

• antiviral suppression

• very low-level infection

HBsAg negative + HBV DNA positive

Possible:

• occult infection

• window period

• assay limitations

• mutant infection

• resolving infection

Clinical context is essential.

35. HBV Genotyping

HBV genotyping identifies the viral genotype.

It can be useful for:

• epidemiological studies

• transmission studies

• understanding natural history

• research

• selected treatment contexts

However:

36. Mutation and Resistance Testing

Genotypic resistance testing may be considered when:

• virological breakthrough occurs

• antiviral resistance is suspected

• prior treatment exposure is significant

• treatment history is complex

Testing generally evaluates:

HBV polymerase/reverse-transcriptase mutations.

37. HDV Testing

Every patient with HBV should be evaluated for:

Hepatitis D virus (HDV)

according to current guideline recommendations and clinical/epidemiological risk.

A common approach is:

Anti-HDV antibody screening

followed by:

HDV RNA

when infection is suspected/confirmed.

This is important because HDV can markedly accelerate HBV-related liver disease.

38. Screening for Coinfections

Depending on clinical context, evaluate for:

• HCV

• HIV

• HDV

These infections can alter:

• natural history

• treatment decisions

• liver disease progression

• reactivation risk

39. HBV Diagnosis in Pregnancy

Pregnancy screening primarily uses:

HBsAg

If positive:

• HBV DNA assessment is important

• maternal liver disease should be evaluated

• prevention of mother-to-child transmission should be planned

High maternal HBV DNA is an important risk factor for perinatal transmission.

40. Diagnosis of HBV Reactivation

HBV reactivation is suspected when a patient with:

• current HBsAg positivity

or

• previous HBV exposure

develops:

Rising HBV DNA

with or without:

ALT elevation

This is especially important during immunosuppressive therapy.

41. HBV in Immunocompromised Patients

A patient may have:

HBsAg negative

but:

anti-HBc positive

and still be at risk of HBV reactivation.

Therefore, pre-immunosuppression screening should generally include appropriate HBV serology, typically:

• HBsAg

• anti-HBc

• anti-HBs

according to the clinical context and guideline.

42. HCC Assessment

HBV diagnosis must eventually lead to:

HCC risk assessment.

Depending on risk:

• liver ultrasound

• AFP where appropriate

• additional imaging for suspicious lesions

may be required.

Important

HCC can occur:

43. Diagnosis in Acute Liver Failure

In a patient with acute severe hepatitis or acute liver failure, assess:

• HBsAg

• IgM anti-HBc

• HBV DNA

• other viral causes

• autoimmune hepatitis

• drug-induced liver injury

• metabolic causes

Fulminant HBV can sometimes have rapidly changing or even declining HBsAg levels.

Therefore:

IgM anti-HBc is particularly important.

44. Laboratory Algorithm for Suspected HBV

Patient with suspected HBV
          ↓
HBsAg + anti-HBc + anti-HBs
          ↓
     HBsAg positive?
       ↙       ↘
     YES        NO
      ↓          ↓
Determine     Anti-HBc?
acute vs       ↙    ↘
chronic      YES     NO
      ↓       ↓       ↓
HBeAg/       Evaluate  Susceptible
anti-HBe     IgM anti-
+ HBV DNA    HBc ± DNA
      ↓
ALT + AST
      ↓
Fibrosis assessment
      ↓
HDV/other coinfections
      ↓
HCC risk assessment
      ↓
Treatment/monitoring decision

45. Diagnosis of Acute HBV

Typical diagnostic combination:

HBsAg positive

IgM anti-HBc positive

Elevated ALT

±

HBV DNA detectable

This strongly supports:

Acute hepatitis B

46. Diagnosis of Chronic HBV

Typical combination:

HBsAg ≥6 months

Total anti-HBc positive

IgM anti-HBc usually negative

±

HBV DNA detectable

±

HBeAg positive

±

ALT elevation

47. Window Period

Classic:

HBsAg −

Anti-HBs −

IgM anti-HBc +

This indicates:

Acute HBV window period

HBV DNA may or may not be detectable.

48. Resolved Infection

Typical:

HBsAg −

Anti-HBs +

Total anti-HBc +

IgM anti-HBc −

Interpretation:

Previous natural HBV infection with recovery.

49. Vaccinated Individual

Typical:

HBsAg −

Anti-HBs +

Anti-HBc −

Interpretation:

Immunity due to vaccination.

50. Completely Susceptible Individual

Typical:

HBsAg −

Anti-HBs −

Anti-HBc −

Interpretation:

No evidence of previous infection or immunity.

51. Common Diagnostic Errors

Error 1

HBsAg negative = no HBV

Incorrect.

Consider window period and occult infection.

Error 2

HBeAg negative = inactive disease

Incorrect.

HBeAg-negative chronic hepatitis exists.

Error 3

Anti-HBs positive = vaccinated

Not necessarily.

Resolved natural infection can also produce anti-HBs.

Check anti-HBc.

Error 4

Anti-HBc positive = current infection

Incorrect.

Anti-HBc persists after recovery.

Error 5

Normal ALT = no significant liver disease

Incorrect.

Fibrosis may exist despite normal ALT.

Error 6

HBV DNA low = no HCC risk

Incorrect.

HCC risk depends on multiple factors and may persist after viral suppression.

Error 7

Positive IgM anti-HBc always means newly acquired HBV

Incorrect.

It can also occur during some chronic HBV flares/reactivation.

52. What Each Test Really Answers

53. The HBV Diagnostic Master Table

54. Microbiology Laboratory Quality Considerations

HBV testing requires attention to:

• specimen identification

• appropriate serum/plasma collection

• assay sensitivity

• internal controls

• calibration

• quality control

• interpretation of weakly reactive results

• confirmatory testing where appropriate

Molecular assays additionally require:

• contamination control

• extraction controls

• amplification controls

• standardized quantification

55. Specimen

Most HBV serological and molecular investigations are performed on:

Serum or plasma

The precise specimen requirements depend on the assay/platform.

For molecular testing, avoid:

• hemolysis where problematic

• improper storage

• repeated freeze-thaw cycles

Follow the manufacturer's validated specimen and storage requirements.

56. Confirmatory Testing

A reactive HBsAg result should be interpreted according to the laboratory's validated algorithm and assay instructions.

Depending on the platform, this may involve:

• repeat testing

• confirmatory neutralization

• an alternative assay

• HBV serological panel

• HBV DNA

The purpose is to distinguish true reactivity from nonspecific/false-positive reactivity.

57. Diagnostic Window and Blood Screening

HBV can be detected at different stages by:

HBV DNA

↓

HBsAg

↓

Anti-HBc

↓

Anti-HBs

Therefore, blood screening strategies use sensitive assays designed to minimize the period during which an infectious donation escapes detection.

58. One Practical HBV Diagnostic Strategy

For a patient newly found to be HBsAg positive:

Step 1

Confirm and characterize HBsAg positivity.

Step 2

Obtain:

• total anti-HBc

• IgM anti-HBc when acute infection is possible

• HBeAg

• anti-HBe

Step 3

Measure:

HBV DNA

Step 4

Assess liver:

• ALT

• AST

• bilirubin

• albumin

• INR

• platelet count

Step 5

Assess fibrosis:

• elastography

• APRI/FIB-4

• imaging ± biopsy when appropriate

Step 6

Evaluate:

• HDV

• HCV

• HIV

• other liver diseases

Step 7

Assess HCC risk.

Step 8

Determine:

Treatment vs monitoring

59. High-Yield Exam Pearls

Pearl 1

HBsAg = current infection.

Pearl 2

HBsAg ≥6 months = chronic infection.

Pearl 3

Anti-HBc = natural exposure.

Pearl 4

Anti-HBs = immunity.

Pearl 5

Vaccination produces anti-HBs but not anti-HBc.

Pearl 6

IgM anti-HBc is the key marker of acute/recent HBV.

Pearl 7

HBV DNA is the best direct marker of viral replication.

Pearl 8

HBeAg is a replication/infectivity marker, not a substitute for HBV DNA.

Pearl 9

HBeAg-negative does not mean inactive.

Pearl 10

Normal ALT does not exclude fibrosis.

Pearl 11

Isolated anti-HBc has multiple possible explanations.

Pearl 12

HBsAg-negative/HBV-DNA-positive infection suggests possibilities such as occult infection, window period or assay-related issues depending on context.

Pearl 13

HBV diagnosis is based on a panel, not one marker.

Pearl 14

HBV DNA should preferably be reported in IU/mL.

Pearl 15

Diagnosis should be followed by fibrosis and HCC risk assessment.

60. One-Minute Revision

HBV Diagnosis

Current infection

HBsAg +

Natural exposure

Anti-HBc +

Recent infection

IgM anti-HBc +

Immunity

Anti-HBs +

Vaccine immunity

Anti-HBs + / anti-HBc −

Viral replication

HBV DNA

HBeAg-positive disease

HBeAg + / usually high HBV DNA

HBeAg-negative active disease

HBeAg − / HBV DNA elevated or fluctuating

Window period

HBsAg − / anti-HBs − / IgM anti-HBc +

Resolved infection

HBsAg − / anti-HBs + / anti-HBc +

Chronic infection

HBsAg ≥6 months

61. Final Take-Home Message

HBV diagnosis is fundamentally a serological and molecular puzzle.

The three most important markers to remember are:

Then add:

and:

The best diagnostic approach therefore combines:

Serology + HBV DNA + liver biochemistry + fibrosis assessment + clinical context.